SCHEMBL29847259

SCHEMBL29847259

CC(c1ccccc1OC(F)(F)F)N1CCc2ncccc2C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 5/20 0.41
▸ PDE2A O00408 1/20 0.41
▸ NPC1 O15118 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ DPP4 P27487 1/20 0.36
▸ DPP7 Q9UHL4 1/20 0.36
▸ TRPV1 Q8NER1 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ P2RY2 P41231 1/20 0.35
▸ P2RY1 P47900 1/20 0.35
▸ P2RY14 Q15391 1/20 0.35
▸ HSD17B13 Q7Z5P4 1/20 0.35
▸ SSTR1 P30872 1/20 0.34
▸ SSTR4 P31391 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ CCNT1 O60563 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29847281 0.90 TRPV1 (0.37) GRM5PDE2ANPC1TP53MAPT
SCHEMBL22470689 0.83 HSD17B13 (0.34) GRM5PDE2AMAPTTHRBHSD17B13
SCHEMBL29847050 0.83 HSD17B13 (0.34) GRM5PDE2AMAPTTHRBHSD17B13
SCHEMBL29846888 0.83 NPC1 (0.39) GRM5PDE2ANPC1TP53MAPT
SCHEMBL29846973 0.77 GRM5 (0.38) GRM5PDE2ANPC1TP53MAPT
SCHEMBL21144746 0.76 GRM5 (0.60) GRM5NPC1TP53MAPTRAB9A
SCHEMBL29846810 0.75 HTR2C (0.44) SMN1; SMN2
SCHEMBL23753820 0.74 FFAR1 (0.35) PDE2A
SCHEMBL29846957 0.74 FFAR1 (0.35) PDE2A
SCHEMBL23753946 0.73 PIK3CG (0.37) MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4105216-B1 DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF GENFLEET THERAPEUTICS SHANGHAI INC (CN) 2026-05-20 — — EP disclosed
CN-115135648-B Dihydronaphthyridones, preparation method and medical application thereof 劲方医药科技(上海)有限公司 2024-02-09 — — CN disclosed
US-20230139111-A1 DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2023-05-04 — — US disclosed
EP-4105216-A1 DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF Genfleet Therapeutics (Shanghai) Inc. (CN) 2022-12-21 — — EP disclosed
CN-115135648-A Dihydronaphthyridinone compounds, preparation method and medical application thereof 劲方医药科技(上海)有限公司 2022-09-30 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230139111-A1 DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF RIPK1, RIPK4, RIPK3 GRM5 2262/4885PDE2A 3042/4885NPC1 1034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback